Teva signs $430 million pact for OncoGenex's cancer adjunct
This article was originally published in Scrip
Executive Summary
Teva is to pay $60 million up front and up to $370 million in milestones to access OncoGenex's lead product, the cancer adjunct therapy candidate OGX-011. However, OncoGenex will have to share the cash with its partner, Isis Pharmaceuticals.